MULTIPLE SCLEROSIS-DMARD

From NeuroRehab.wiki

Revision as of 03:41, 21 February 2023 by Dr Appukutty Manickam (talk | contribs) (Imported from text file)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

SUMMARY

ORAL MEDS (Common SE : lymphopenia)
1. Teriflunomide: active metabolite of leflunomide, pyrimidine antagonist
2. Fingolimod: sphingosine-1-phosphate receptor modulator
3. Cladribine: purine analogue that selectively suppresses lymphocytes
4. Dimethyl fumarate: immune modulator

INJECTABLES

5. Interferon-b
6. Glatiramer

INFUSIONS
7. Alemtuzumab: anti-CD52 antibody
8. Ocrelizumab: anti-CD20 antibody, only DMARD for primary progressive MS
9. Natalizumab (Tysabri): anti-alpha-4-integrin antibody


Reference(s)

Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].